Zydus Lifesciences on February 5 reported a 30 percent increase in its consolidated net profit at Rs 1,023 crore for the quarter ended December 31, 2024, driven by strong sales in domestic and US markets. The company had posted a net profit of Rs 789 crore in the same quarter last year.
Zydus Life reported the revenue from operations grew 17 percent to Rs 5,269 crore in the third quarter, compared to Rs 4,505 crore in the year-ago period, the company said in a statement.
Managing Director Sharvil Patel said the company’s performance was supported by strong execution in the US, market share gains in key therapy segments in India, and a well-placed international portfolio.
“We are pleased with the sustained growth momentum across our businesses, which keeps us on track to achieve our fiscal 2025 goal of double-digit growth with improved profitability,” Patel said.
He added that the company is focused on building long-term growth levers while keeping patient centricity and quality at the core of its strategy.
Shares of the company were trading flat at Rs 978.45 per share on the NSE, up 0.46 percent at around 2:30 PM.
Disclaimer: The views and investment tips expressed by experts on Moneycontrol are their own and not those of the website or its management. Moneycontrol advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.